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Abstract
Purpose Diagnosis of spondylodiscitis (SD) may be challenging due to the nonspecific clinical and laboratory findings and the
need to perform various diagnostic tests including serologic, imaging, and microbiological examinations. Homogeneous man-
agement of SD diagnosis through international, multidisciplinary guidance would improve the sensitivity of diagnosis and lead to
better patient outcome.
Methods An expert specialist team, comprising nuclear medicine physicians appointed by the European Association of Nuclear
Medicine (EANM), neuroradiologists appointed by the European Society of Neuroradiology (ESNR), and infectious diseases
specialists appointed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), reviewed the
literature from January 2006 to December 2015 and proposed 20 consensus statements in answer to clinical questions regarding
SD diagnosis. The statements were graded by level of evidence level according to the 2011 Oxford Centre for Evidence-based
Medicine criteria and included in this consensus document for the diagnosis of SD in adults. The consensus statements are the
result of literature review according to PICO (P:population/patients, I:intervention/indicator, C:comparator/control, O:outcome)
criteria.
Evidence-based recommendations on the management of adult patients with SD, with particular attention to radiologic and
nuclear medicine diagnosis, were proposed after a systematic review of the literature in the areas of nuclear medicine, radiology,
infectious diseases, and microbiology.
Results A diagnostic flow chart was developed based on the 20 consensus statements, scored by level of evidence according to
the Oxford Centre for Evidence-based Medicine criteria.
Conclusions This consensus document was developed with a final diagnostic flow chart for SD diagnosis as an aid for profes-
sionals in many fields, especially nuclear medicine physicians, radiologists, and orthopaedic and infectious diseases specialists.
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Introduction
Spinal infections include vertebral osteomyelitis (infection of
the vertebral body), discitis (infection of the intervertebral
disc), and spondylodiscitis (SD) (infection of two adjacent
vertebral bodies and their intervertebral disc) [1, 2].
Our article will focus specifically on SD in adult patients.
The incidence of SD in developed countries ranges from 4
to 24 per million per year [3], and has been increasing in
recent decades as a result of several factors, including an in-
crease in the susceptible population (i.e. aged persons, patients
with immunosuppression, diabetes mellitus, chronic renal or
liver diseases, long-term steroid use); a rise in the number of
invasive procedures, especially spinal surgery and improve-
ments in diagnostic sensitivity [3].
It occurs at any age but is most frequent in the fifth to
seventh decades. Men are affected more frequently than wom-
en [4–6].
In adults, spinal infections are initially localised in the an-
terior part of the vertebral body, which presents more vascular
structures [2, 7, 8], thus extending into the adjacent tissues
(intervertebral disc and adjacent vertebrae). The exact anatom-
ical location of the infective process enables the classification
of SD in anterior, posterior, spinal canal, or bone graft sites
[1].
The most frequent site of vertebral infection is the lumbar
spine (45%), followed by the dorsal spine (35%) and the cer-
vical tract (20%) [2–9].
SD can be described aetiologically as pyogenic, granulo-
matous (tuberculous, brucellar, fungal), or parasitic [10], and
clinically as primary or secondary.
In primary SD, pathogens can infect the spine by
haematogenous spread or by spread from contiguous tissues.
Staphylococcus aureus is the most frequently isolated patho-
gen (55–80% of cases) [4–6, 8–17]. Around 7–33% of pyo-
genic SD are caused by Enterobacteriaceae, mostly
Escherichia coli, followed by Proteus and Klebsiella species
[5, 18–23]. Coagulase-negative staphylococci (CoNS) ac-
count for 5–16% of cases [17, 19–22]. Brucellosis, a common
zoonosis in endemic areas (Mediterranean Basin, Latin
America, the Middle East, parts of Africa, and Western
Asia) can account for 21–48% of spinal infections [19, 21].
Tuberculosis (TB) is among the commonest aetiological
agents of spinal infection worldwide, and is responsible for
9–46% of SD in developed countries [19, 21, 23].
Secondary SD occurs due to direct contamination by mi-
croorganisms in surgical or interventional procedures [7–9,
24, 25]. The incidence of secondary SD varies according to
the type of surgical procedure, ranging from 1 to 7% [8,
26–31].
Postoperative infections are caused mainly by S. aureus,
isolated in almost 50% of cases, and CoNS [32–34]. Gram-
negative bacteria may also cause post-surgical SD, with
E. coli, Pseudomonas aeruginosa, Klebsiella pneumoniae,
Enterobacter cloacae, Bacteroides, and Proteus species
[32–34] representing the most frequently isolated Gram-
negative bacteria.
The diagnosis of SD may be challenging due to the unspe-
cific clinical features and laboratory findings and the need to
perform different diagnostic tests including serologic, imag-
ing, and microbiological examinations.
The clinical features include severe spine pain with or with-
out fever. Neurological deficit, including leg weakness, paral-
ysis, sensory deficit, radiculopathy, and loss of sphincter con-
trol, are present in one-third of cases [35].
Laboratory findings, although not specific, include elevat-
ed levels of C-reactive protein (CRP) and increased erythro-
cyte sedimentation rate (ESR) [35].
Differential diagnosis of SD includes other spine patholo-
gies such as erosive osteochondrosis, osteoporotic and patho-
l og i c a l f r a c tu r e , sp ine me t a s t a s i s , anky lo s ing
spondyloarthritis, Scheuermann’s disease, and post-surgical
changes.
Long courses of antibiotic therapy are usually necessary,
and if the disease is not adequately controlled, a surgical ap-
proach is often required [36].
Aim of this consensus document
Diagnosis of SD is based on clinical, laboratory, and imaging
findings. In recent decades, the sensitivity of SD diagnosis has
been significantly improved; however, it is still difficult and is
often delayed or missed.
Early diagnosis of SD, with the identification of the aetiology
and description of the location, extent, and severity of the infec-
tious process, as well as the presence of complications, is funda-
mental to supporting appropriate therapeutic management.
Although guidelines for the diagnosis of SD have been pub-
lished previously, the diagnostic imaging of spine infection is still
an issue. The Infectious Diseases Society of America (IDSA)
guidelines, published in 2015, only provide guidance for diag-
nosis and treatment of native vertebral osteomyelitis (NVO),
without addressing secondary SD [36]. Moreover, limited con-
sideration is given to radiologic and nuclear medicine techniques
for the assessment of spine infection.
Qualified members of the EuropeanAssociation of Nuclear
Medicine (EANM), European Society of Clinical
Microbiology and Infectious Diseases (ESCMID), and
European Society of Neuroradiology (ESNR) previously
utilised a multidisciplinary approach to design a diagnostic
flow chart for the management of SD [37].
Importantly, the implementation of radiologic and nuclear
medicine techniques for the assessment of spine infection still
varies widely, with heterogeneity in technical aspects that per-
sists across countries in Europe with different levels of
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experience and preferences. The recognition of this problem
led to the awareness among members of EANM, ESCMID,
and ESNR that practical guidance is needed to establish stan-
dards for imaging in SD using MRI, 99mTc-methylene
diphosphonate (MDP) or 99mTc-hydroxy diphosphonate
(HDP) bone scan, 67Ga scintigraphy, and [18F]FDG positron
emission tomography (PET)/computed tomography (CT).
Management of SD diagnosis through international multi-
disciplinary consensus would improve diagnostic accuracy
and thus lead to better outcomes for patients with SD.
After a systematic review of the literature in the areas of
nuclear medicine, radiology, infectious diseases, and microbi-
ology, evidence-based recommendations have been proposed
for the management of adult patients with SD, with particular
attention to radiologic and nuclear medicine diagnosis. This
consensus document was developed as an aid for profes-
sionals inmany fields, especially nuclear medicine physicians,
radiologists, and orthopaedic and infectious diseases
specialists.
Methodology
A guideline expert panel was established, with different ex-
perts assigned a topic for review and presentation to the entire
group. The panel comprised infectious disease specialists
(ESCMID members), nuclear medicine physicians (EANM
members), and neuroradiologists (ESNR members). EANM
participants were selected by the EANM Committee on
Inflammation and Infection on the basis of their publication
record and a personal statement. ESCMID and ESNR partic-
ipants were selected by the governing boards of the respective
societies.
The panel identified 20 clinical questions to address. Panel
members thoroughly reviewed the literature pertinent to each
of the questions according to PICO (P: population/patients, I:
intervention/indicator, C: comparator/control, O: outcome)
criteria [38]. Articles presenting data pertaining to the diagno-
sis of SD were identified through computerised literature
searches using MEDLINE (National Library of Medicine,
Bethesda, MD), EMBASE, and the Cochrane database and
by reviewing the references of retrieved articles. For develop-
ment of the background section, we also reviewed articles
describing the epidemiology of SD. Index search terms were
selected according to the Oxford Centre for Evidence-based
Medicine, as reported in Appendix 1.
The search was restricted to full articles published in
English from January 2006 to December 2015 and including
adult patients (>16 years of age). No attempt was made to
obtain information on unpublished studies. Since data from
randomised clinical trials were expected to be limited, we also
reviewed non-randomised controlled clinical trials and cohort
and case–control studies. Single case reports and reviews were
excluded, as well as studies including fewer than 10 patients.
After the literature review, the panel members elaborated the
statements to be included and graded the level of evidence
according to the 2011 Oxford Centre for Evidence-based
Medicine criteria [38]. Statements were circulated first among
each working group and then among all participants.
All working groups met several times between 2014 and
2016 in order to reach a consensus on the final version of each
statement.
Finally, based on the results obtained from each search, we
developed a diagnostic flow chart for SD (Fig. 1).
Diagnostic tools
Radiologic imaging
The role of radiology is to define the correct diagnosis as early
as possible, to assist in percutaneous biopsy (if needed) and in
follow-up of the disease, and to evaluate the presence of com-
plications [39–42].
Plain film X-ray
Plain radiographs are usually the first imaging modality re-
quested when infection is suspected [13, 43], despite their
low sensitivity and specificity [44, 45]; they are also helpful
for viewing implant loosening. Imaging includes
anteroposterior and lateral projections of the suspected spinal
segment [44, 45].
The detection of signs and abnormalities depends on the
entity and can be seen when bone destruction exceeds 30%.
Signs are usually not apparent on plain radiographs until 2–
8 weeks after the initial symptoms [44, 45], and it should be
considered that changes caused by infection may not be as
apparent in patients with degenerative signs on imaging stud-
ies [44].
The main findings are blurred appearance of the cortical
bone, erosion of the anterior corner of the vertebral end plate,
progressive loss of disc height, narrowing of the intervertebral
space, and development of osteolysis with further destruction
of the subchondral plate. Tumefaction of the soft tissue and
pre- or paravertebral soft tissue densities with fluid level may
also be detected.
In advanced disease, the erosions can involve the entire
vertebral end plate, and signs of bone reformation comprising
peripheral sclerosis, osteophytosis, and a build-up of
osteolytic lesions can coexist. All of these lesions may lead
to significant osteolysis and vertebral compression, and disor-
ders of spinal deformity may arise. Rarely, with indolent in-
fections, the reactive sclerosis may produce an “ivory” appear-
ance as the only evident change [46].
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Magnetic resonance imaging (MRI)
MRI should be the first imaging modality performed, given its
high sensitivity, specificity, and accuracy (reported as 96%,
92%, and 94%, respectively) for the diagnosis of SD. This is
related to the high contrast resolution, direct multiplanar im-
aging capability, high sensitivity for soft tissue and bone mar-
row abnormalities, and the absence of ionising radiation,
which make MRI the reference standard for imaging of spinal
infections even in the postoperative setting, whereas it is usu-
ally not indicated in patient follow-up, as MRI findings can
worsen despite clinical improvement [47–53].
The main utility of MRI is the possibility for diagnosis in
the early stages of the infection, within the first 2 weeks in
more than 50% of cases, when other radiologic imaging mo-
dalities are still normal. In a further 20% of patients, positive
findings can be detected in the following 2 weeks, and so in
the case of persistent clinical symptoms with a non-diagnostic
earlyMRI scan, it is recommended that the exam be repeated a
few days later [54].
The MRI examination should include the following
sequences:
& STIR or fat-saturated T2-weighted (T2-w) sequences that
are fluid-sensitive and highly sensitive for the detection of
inflammatory oedema [better than T2-w spin-echo (SE)
sequences]
& T1-weighted (T1-w) SE fat-suppressed pre- and post-
administration of intravenous (i.v.) injection of contrast
media, for morphological study and to differentiate be-
tween vascularised and non-vascularised lesions and/or
necrotic inflammatory components
The infection usually begins near the end plate in the an-
terolateral vertebral body; the infection and inflammation
Fig. 1 Diagnostic flow chart to be followed in case of suspected
haematogenous or post-surgical SD. The predominant role of MRI in
SD of haematogenous origin and of [18F]FDG-PET/CT in post-surgical
SD is highlighted. *MRI should be performed with at least a 1.5 T mag-
net, with T1, T2 fat-suppressed, or short-tau inversion recovery (STIR)
sequences with and without contrast medium. **Although indicated, in
the case of PET/CT unavailability, MRI can be performed instead, with
lower diagnostic accuracy. A combined 99mTc-MDP+ 67Ga-citrate scin-
tigraphy [with single-photon emission computed tomography (SPECT)/
CT acquisitions] can also be performed. In these cases, if only MRI is
performed or if [18F]FDG-PET/CT is inconclusive, a CT-guided biopsy is
strongly indicated for final diagnosis. PET/MRI, if available, can be
substituted for PET/CT
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cause marrow oedema, with a decreased signal in T1-w se-
quences, increased signal in T2-w sequences, and contrast
enhancement in T1-w sequences after i.v. contrast injection
[48–50].
When the erosion of the end plates occurs, the hypo-
intense band of cortical bone appears thinned or absent
[49]. An early sign of discitis is the loss of the
intranuclear clef t seen in T2-w sequences. The
intranuclear cleft consists of a linear transverse hypo-
intense band within the central part of the disc in the
sagittal or coronal plane; it is a normal aspect of the de-
generative disc and can be detected in more than 90% of
patients older than 40 years.
Following i.v. contrast media injection, disc enhance-
ment may be homogeneous or patchy non-confluent areas
of enhancement, and thick or thin areas of peripheral en-
hancement may be seen. If subsequently the infection in-
volves all of the vertebral body and the intervertebral disc
as well as the surrounding tissues, a hyper-intense signal
on T2-w sequences or moderate and heterogeneous tissue
enhancement in the T1-w sequences post-i.v. contrast in-
jection is usually seen. If abscesses are present, they are
seen as fluid collection with heterogeneous signal in T1-w
sequences and with ring-enhancing thickened walls [49,
50]. When diffuse enhancement throughout the mass is
seen, this is more consistent with granulation tissue, but
if the clinical picture is suggestive of infection, the mass
should be treated as an epidural abscess [12].
Spinal neoplasms on MRI may mimic findings in in-
fectious discitis, especially when they are tubercular in
aetiology, since both may have a low signal on T1-w
and high signal on T2-w; the involvement of disc space
helps in distinguishing infections from neoplasms, as tu-
mours usually do not enter the disc space [50–52]. The
aetiological diagnosis of SD can be made only by isolat-
ing the causative organism, but some imaging findings
may be suggestive of a specific aetiology. For example,
meningeal involvement, sub-ligamentous spread of infec-
tion to three or more vertebral levels, and paravertebral
and intra-osseous abscesses with a thin, smooth wall are
typical features of tubercular aetiology with relative spar-
ing of the intervertebral disc [27].
A disadvantage of MRI is related to the over-estimation
of the amount of infected tissue, as some of the signal
changes are reactive; furthermore, in the presence of se-
vere degenerative disc disease leading to oedema-like
changes in the end plates and the adjacent discs, MRI
may give false-positive results [53]. Bone involvement is
not as well visualised as by CT, and in the preoperative
assessment, CT scan may be more useful for defining the
amount of tissue necrosis that requires surgical debride-
ment. Also, in the postoperative setting, CT may be pre-
ferred to MR to avoid difficulty in reading the exam due
to the increased T2 signal and contrast uptake at the sur-
gical site. For the same reasons, MRI is not as sensitive
for the onset of reparative changes; in this sense, there is
evidence suggesting that some MRI changes may persist
or even worsen during treatment, even in the presence of
clinical improvement and negative lab tests, and may lead
to unnecessary surgery [54]. The signs of a healing pro-
cess include the following: reduction in the amount of
oedema due to soft tissue inflammation; loss of gadolini-
um enhancement, which appears later (few weeks to few
months after the onset of treatment), so the detection of
some enhancement in patients with clinical improvement
is not necessarily related to therapy failure but to an in-
crease in granulation tissue due to the healing process;
progressive bone restoration that may be seen after a me-
dian of 15 weeks as a rim of high signal intensity on T1-w
images occurring at the lesion edges [53, 54].
Computed tomography (CT)
Computed tomography (CT) is readily available, easy to per-
form, and faster than MRI, and represents the best modality
for the detection of bony abnormalities as minimal erosion of
the end plates (before they become visible on X-ray), small
vertebral foci of infection, or pathological calcification sug-
gestive of TB [55].
It may be complementary to MRI, providing better defini-
tion of the extent of bony involvement, whereas MR is more
useful in the evaluation of the central canal and the spinal cord
[56, 57]. Contrast media is usually not injected except when
MRI cannot be performed.
The main findings in an active state of infection are loss of
bone architecture with areas of transparency and soft tissue
replacement, end-plate erosion, and collapse of the disc space
with abscess formation [46]. In the case of spreading in pre-
and paravertebral locations, soft tissue masses may be seen;
for the evaluation of these structures and of the involvement of
the thecal sac, MRI is certainly more indicated [48, 49].
CT is currently used mostly for percutaneous needle
biopsy and percutaneous drainage of abscesses and is an
excellent modality in the early postoperative evaluation of
spinal alignment and implant positioning [58, 59], even
though, in presence of stainless steel implants, the image
quality may be low due to implant-related artefacts. It is
particularly useful when MR is contraindicated, not avail-
able, or equivocal [60, 61].
Even though CT is inferior to MRI in imaging soft tissue,
the affected discs may be seen with hypodense areas in this
context [3], soft tissue swelling and obliteration of fat planes
around the vertebral bodies may be detected [54], and
paravertebral abscesses involving the psoas can be identified
with contrast [62].
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Image-guided biopsy
Image-guided biopsy of the infected tissue is an important tool
in the diagnosis of SD. Histopathological and microbiological
examinations of biopsy specimens can enable a definite diag-
nosis of SD and can identify the causative pathogen.
The first non-invasive step for the identification of the
possible aetiological agent of SD is performing blood cul-
tures. It has been reported that they grow the causative
microorganism in up to 60% of cases [13, 18, 21, 22, 54,
63]. The percentage of positive blood cultures is lower in
postoperative infections [62]. Three blood samples must be
collected at three different times for cultures. Urine and/or
sputum cultures and swabs from any possible portal of
infection should also be considered to investigate a prima-
ry focus of infection. Bone marrow aspiration may be use-
ful if brucellosis is suspected, as well as urine and sputum
for acid-alcohol-fast bacilli [3, 54].
CT or fluoroscopy-guided biopsy is the first invasive diag-
nostic step [58, 59, 64–67]. It is able to identify the bacterial
agent in up to 91% of patients [13, 54]. Biopsy is the main
procedure in patients with postoperative spondylodiscitis, as
blood cultures in these patients are frequently negative [67].
The diagnostic yield of image-guided biopsy cultures
varies widely between studies and can be influenced by sev-
eral factors, including previous antibiotic therapy, patient clin-
ical features, radiologist expertise, and number of samples
sent. Biopsy specimens should be sent for Gram staining,
aerobic and anaerobic cultures, and histopathology, since it
can distinguish between pyogenic and granulomatous disease,
and it is mandatory if tumour aetiology is suspected [3, 13,
54]. In patients with specific risk factors, cultures for
mycobacteria, fungi, and Brucella should also be performed;
molecular methods can be used as well to improve the chances
of identifying pathogens [68, 69].
Biopsy must be performed under conditions of surgical
asepsis, with local anaesthesia and conscious sedation, and
with the patient in a prone position. The main points of access
used are as follows: anterior for cervical spine lesions,
transpedicular and posterolateral for the lumbar spine, and
inter-costotransverse for the thoracic spine. Typically, a small
incision is made to allow needle entry and an 18-gauge trocar
is used to collect at least four bone samples (two from the
upper end plate and two from the lower end plate). The disc
sample has to be taken with a toothed micro-needle, according
to disc compactness. At least three samples should be sent for
microbiological analysis and two for pathological analysis;
one sample will be frozen at −20° to perform any subsequent
polymerase chain reaction (PCR), if needed. At the end of the
procedure, the disc should be rinsed with saline solution,
which is aspirated back and sent for culture. Blood cultures
can be performed within 4 h of completion of the biopsy. It is
important that material is sent and processed quickly to avoid
loss of viability of fragile or fastidious organisms [36, 42, 54,
58, 59, 62].
Nuclear medicine imaging
Conventional radiopharmaceuticals for diagnosis of infection,
such as labelled autologous leukocytes [white blood cells
(WBC)], can fail to detect vertebral osteomyelitis, and the site
of infection often appears as a “cold spot” in the scan [70–78].
Radiopharmaceuticals available for the study of spine infec-
tion include labelled diphosphonates (99mTc-MDP/HDP),
67gallium citrate (67Ga), and fluorodeoxyglucose labelled with
fluorine-18 ([18F]FDG). Each has its advantages and
limitations.
Scintigraphy with 99mTc-MDP/HDP and 67Ga-citrate
A review of 30 original articles published between 1984 and
2004 regarding different radionuclide imaging for diagnosis
of spine infections [78] showed that approximately 324 le-
sions were studied with bone scans, with sensitivity of
81.4% and specificity of 40.7%. The advantages of this radio-
pharmaceutical include low cost, low radiation burden, and
single-day imaging procedure. It is limited, however, by low
specificity.
Prandini et al. reported sensitivity of 86.3% and specificity
of 35.8% in 223 lesions investigated with 67Ga for suspected
vertebral infection [78, 79].
A combination of 99mTc-MDP bone scintigraphy and 67Ga-
citrate can be used to increase diagnostic accuracy, particularly
in the case of post-surgical infections or to complement doubt-
ful MRI findings in the case of primary infections [80–82].
Pros and cons
The advantage of 67Ga and 99mTc-MDP is their ready avail-
ability. Limitations of 67Ga include a higher radiation burden
and time-consuming acquisition (up to 48 h and sometimes
72 h).
Interpretation criteria
In primary spine infections, the comparison of 99mTc-MDP
bone scintigraphy with 67Ga-citrate may enable differentiation
of infectious from inflammatory and degenerative disease.
When 67Ga-citrate uptake is higher than 99mTc-MDP, the ver-
tebral pathology may have an infectious origin, while higher
uptake of 99mTc-MDP than 67Ga-citrate may indicate a degen-
erative origin [81]. The overall accuracy of bone/67Ga imag-
ing is about 65–80% [70, 81, 82].
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Influence of medication
Iron therapy (Ferrograd), chemotherapy (even 3 months after
the end of therapy), corticosteroids (prednisolone), and Gd-
DTPA (if administered 24 h before) can alter the qualitative
analysis of 67Ga-citrate.
PET or PET/CT with [18F]FDG
The role of [18F]FDG for diagnosing spinal infection has been
investigated extensively. [18F]FDG is transported into cells by
glucose transporters GLUT1 and GLUT3 and, after phosphor-
ylation by hexokinase, remains inside and is not metabolised.
The uptake of [18F]FDG is related to the cell metabolic rate
and the number of glucose transporters on the cell surface
[83]. Kubota et al. demonstrated that [18F]FDG uptake in tu-
mours was, in fact, partly the result of newly formed granula-
tion tissue and activated macrophages associated with tumour
necrosis and growth [84]. Using autoradiography, the same
investigators demonstrated that [18F]FDG uptake by non-
neoplastic cells was even higher than its accumulation in via-
ble tumour cells [85]. Detailed histopathologic and autoradio-
graphic analysis of an experimental soft tissue abscess model
in rats showed that the highest FDG uptake was within areas
of inflammatory cell infiltrate, which was composed primarily
of neutrophils in the acute phase and macrophages in the
chronic phase [86]. In activated inflammatory cells such as
neutrophils, lymphocytes, monocytes, and macrophages, an
increase in both the number and expression of glucose trans-
porters is found, as well as increased affinity of these trans-
porters for deoxyglucose [86].
PET or PET/CT with [18F]FDG has shown very high sen-
sitivity with relatively low specificity in diagnosing spine in-
fections. In 2006, Rosen et al. reported the presence of abnor-
mal spinal [18F]FDG uptake, classified on a scale of 0–4,
showing the relationship between the severity of findings on
18F-FDG PET and the severity of degenerative spinal disease
on CT [87], which confirmed the occasional non-specificity of
[18F]FDG uptake in the spine. Ohtori et al. and Stumpe et al.,
however, found a high rate for the detect ion of
spondylodiscitis if [18F]FDG-PET was used in addition to
conventional radiologic imaging [88, 89]. In a prospective
cohort study with over 300 patients, Ohtori et al. demonstrated
that a definitive diagnosis of spine infection was achieved
more often when [18F]FDG-PET was utilised [88]. This was
reported specifically in patients with spinal infections present-
ing as Modic type 1 signals on MRI, which made the distinc-
tion between common Modic changes and spine infection
challenging. [18F]FDG-PET imaging is useful in the work-
up of patients with metallic implants, since it is not affected
by artefacts. In fact, [18F]FDG-PET imaging can also provide
results in a short time (within 2 h) with a resolution of up to 4–
5 mm [87].
Kim et al. evaluated the prognostic effectiveness of follow-
up imaging with [18F]FDG-PET/CT in 30 patients with spinal
infection after therapy. The authors found that [18F]FDG-PET/
CT is useful for the evaluation of residual infection after treat-
ment. They suggest using quantitative indexes, such as the
standardised uptake value (SUV), to evaluate the residual in-
fection [90].
Fuster et al. prospectively evaluated the usefulness of
[18F]FDG-PET/CT in comparison to bone scan and 67Ga scin-
tigraphy for the diagnosis of SD in 34 patients, showing the
best diagnostic accuracy for [18F]FDG-PET/CT [sensitivity
89%, specificity 88%, positive predictive value (PPV) 89%,
negative predictive value (NPV) 87%, accuracy 88%] [82].
Hungenbach et al. reported sensitivity of 86% and speci-
ficity of 95% for the diagnosis of SD using [18F]FDG-PET.
The authors note that the use of [18F]FDG uptake patterns as
interpretation criteria helps to predict or exclude SD.
[18F]FDG -PET is therefore an important tool in inflammation
imaging and can be used in the diagnostic algorithm of diffi-
cult cases with suspected SD. In contrast, a positive
[18F]FDG-PET result does not always clearly establish the
cause of increased [18F]FDG uptake [91].
Despite the relatively low specificity of radiopharmaceuti-
cals available to study spine infection, radionuclide imaging is
strongly recommended for assessing disease activity during
follow-up after medical therapy [92, 93].
Another interpretation criterion for [18F]FDG-PET/CT
findings was proposed by Riccio et al., who state that
[18F]FDG uptake confined to the margins of a destroyed disc
after antibiotic therapy for pyogenic spine infection must not
be considered indicative of persistent infection, and likely rep-
resents mechanically induced inflammation. [18F]FDG uptake
in bone or soft tissue does indicate active infection.
Quantification of activity could not reliably differentiate pa-
tients with active infection from those without active infection
and those who had successful response to therapy. The pattern
of activity is critical for accurate interpretation [94].
Lee et al. observed in a preliminary study that SUVmax
seemed to reflect the activity of infectious spondylitis in 22
patients. [18F]FDG-PET/CT may also be complementary to
MRI for differentiating pyogenic and tuberculous spondylitis
[95].
Published data indicate that [18F]FDG-PET/CT is superior
to 67Ga for the diagnosis of spinal infection and paraspinal soft
tissue infection [82], and should be used in selected cases as
an alternative to MRI [3, 61, 94–109]. All studies in which a
comparison between MRI and [18F]FDG-PET/CT was per-
formed have shown that a combination of the two techniques
detects spinal infection in 100% of patients [102, 110, 111].
Because of the suboptimal specificity of [18F]FDG, alter-
native experimental radiotracers such as radiolabelled antibi-
otics [112] and radiolabelled vitamin [113, 114] are being
developed and tested. Although the results obtained in
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preliminary studies are highly encouraging, full validation in
the clinical setting requires further large-scale studies.
Pros and cons
The advantages of [18F]FDG include very high NPV, high-
quality imaging, and short acquisition time. Disadvantages
include relatively low specificity (ranging from 35.8% to
87.9%), and the inability of [18F]FDG-PET/CT to reliably
differentiate infection from neoplastic lesions or pronounced
degenerative vertebral disease [87]. Other limitations are
scarce availability, non-negligible radiation burden, and
higher costs.
Interpretation criteria
The qualitative analysis of [18F]FDG-PET is positive when
[18F]FDG uptake is higher than that in healthy vertebral bone
tissue. Only one study proposes a connection between differ-
ent patterns (score 0–4) of 18F-FDG uptake and different states
of spine infection diseases, as follows:
“Score 0: Normal findings and physiological [18F]FDG
distribution (consistent with no infection), Score 1:
Slightly elevated uptake in the inter- or paravertebral
region (consistent with no infection), Score 2: Clearly
elevated uptake of a linear or disciform pattern in the
intervertebral space (consistent with discitis), Score 3:
Clearly elevated uptake of a linear or disciform pattern
in the intervertebral space and involvement of ground or
cover plate or both plates of the adjacent vertebrae (con-
sistent with SD), Score 4: Clearly elevated uptake of a
linear or disciform pattern in the intervertebral space and
involvement of ground or cover plate or both plates of
the adjacent vertebrae + surrounding soft-tissue abscess
(consistent with SD)” [91].
Influence of medication
Corticosteroids, antiepileptics, catecholamines, and chemo-
therapy (within 1 month after the end of therapy) can alter
the qualitative analysis of [18F]FDG.
Gemmel et al. proposed a diagnostic algorithm based on
the analysis of many relevant papers on diagnostic imaging
published from 1986 to 2004. This algorithm separated SD of
a non-violated spine from post-surgical/post-traumatic SD.
The reported diagnostic method of choice was MRI in the first
case (non-violated spine), followed by 99mTc-MDP bone scin-
tigraphy with 67Ga-citrate or [18F]FDG-PETwhen MRI is not
readily available or is contraindicated. In the non-violated
spine, the diagnostic choice is based on the presence of me-
tallic implants: the algorithm recommends [18F]FDG-PET as
the first choice in patients with metallic implants (to overcome
the problem of artefacts with MRI), keeping in mind that a
false-positive finding is possible, likely owing to aseptic gran-
ulomatous reactions. In the absence of metallic implants, the
authors suggest MRI, if possible, or [18F]FDG-PET, noting
the possibility of false-positive findings up to 12 months
post-event for MRI and up to 6 months for [18F]FDG-PET.
67Ga-citrate SPECT is suggested in patients without metallic
implants when MRI and [18F]FDG-PET are not available
[115].
With the advent of hybrid imaging, and given the increas-
ing presence of available data on SPECT/CT, PET/CT, and
PET/MRI, we believe that this algorithm needs to be
upgraded. The algorithm also lacks information about incon-
clusive findings of diagnostic imaging and the final step to
take in the case of positive results.
Comparison with published guidelines
There are two available guidelines on SD: the Infectious
Diseases Society of America (IDSA) guidance on native ver-
tebral osteomyelitis published in 2015 [36], and guidance
from the French Infectious Diseases Society (SPILF), pub-
lished in 2007 [68].
The IDSA guidelines [36] were prepared by a panel of
experts (infectologists, orthopaedic specialists, rheumatolo-
gists, and neuroradiologists) without the involvement of nu-
clear medicine specialists. The GRADE system [Grading of
Recommendations, Assessment, Development and
Evaluations] is used to evaluate the quality of evidence. It is
suggested that MRI be performed as a first diagnostic imaging
modality when native vertebral osteomyelitis is suspected,
although there is no detailed description of the MRI acquisi-
tion modality.
With regard to biopsy, IDSA notes that the gauge of the
needle and the administration of antibiotics during the biopsy
procedure have no significant impact on outcome.
During follow-up, PCR and ESR assay is recommended,
while MRI should be performed only in the case of clinical
worsening, followed by new biopsy.
The use of nuclear medicine (combination of spine
67gallium/99mTc bone scan, or CT scan or PET scan) is sug-
gested if MRI cannot be obtained.
The SPILF 2007 guidelines [68], formulated by a larger
panel of experts (infectivologists, orthopaedic specialists,
anatomopathologists, neurosurgeons, neuroradiologists, and
nuclear medicine specialists), suggest X-ray as the first diag-
nostic imaging modality in cases of suspected vertebral oste-
omyelitis, followed by MRI. There is a detailed description of
the acquisition modality of MRI (use of fat suppression se-
quences and i.v. contrast) as well as the modalities for the
execution of the biopsy. The use of nuclear medicine or CT
is suggested if MRI cannot be obtained.
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During follow-up, PCR assay and X-ray are recommended,
while MRI should be performed only in the case of clinical
worsening.
Consensus statements
SD should be suspected in patients with new
or worsening spine pain and/or new myelo-radicular
symptoms, and at least one of the following: fever,
elevated ESR or CRP, bloodstream infection,
or infective endocarditis
Level of evidence: 4
The symptoms of SD are nonspecific and the onset is insidi-
ous. As a result, diagnosis of SD may be difficult. Regarding
clinical symptoms, back or neck pain is frequently reported,
although some studies found that up to 15% of patients can be
pain-free [3, 35]. Fever is less common, occurring in about
50% of patients. Neurological deficits including leg weakness,
paralysis, sensory deficit, radiculopathy, and loss of sphincter
control may be present. Elevated ESR, CPR, andWBC counts
are variably present.
In all patients with suspicion of SD, an accurate medical
history should be obtained, with special attention to prior sur-
gical procedures, history of urinary tract infection, blood-
stream infection, skin or soft tissue infection, signs and symp-
toms of endocarditis, and history of intravenous drug use.
CRP, ESR, and WBC counts should always be
performed in patients with suspected SD
Level of evidence: 4
Elevated ESR, CPR, and WBC counts are variably present in
SD. The sensitivity of elevated ESR or CRP in patients with
back pain ranges from 94% to 100% [10, 19, 116–141], but
the specificity is low. The inflammatory markers are useful to
rule out the presence of an infection or a malignancy in pa-
tients with back pain. WBC counts are normal in up to 40% of
patients with SD [35].
Blood cultures (for both aerobic and anaerobic
bacteria) should always be performed in patients
with suspected SD
Level of evidence: 4
Since the pathogenesis of SD frequently involves
haematogenous spread, blood cultures could enable the
identification of the bacterial agents of SD, with reported
microbiological diagnosis varying between 20% and 60%
[142–147]. The sensitivity of blood cultures is lower in
postoperative infections [63] and higher in patients with
fever [116]. At least two bacterial blood culture (aerobic
and anaerobic) sets should be routinely performed for all
patients with suspected SD [147]. Blood cultures may also
allow the diagnosis of candidemia in patients with fungal
SD. In patients with epidemiological risk factors for bru-
cellosis, blood cultures need to be incubated for up to
2 weeks.
For patients with suspected SD and epidemiological
risk factors for brucellosis, specific serological tests
should be performed
Level of evidence: 4
Brucellosis is a common zoonosis in endemic areas, with
high incidence in countries of the Mediterranean Basin,
Latin America, the Middle East, parts of Africa, and
Western Asia. In patients with suspected SD reporting
travel to or residence in endemic countries or with a his-
tory of consumption of unpasteurised products or occupa-
tional history, serological test for brucellosis should be
performed. The Coombs test is commonly used for the
diagnosis of brucellosis [148, 149]; in one study, a titer
of ≥1:160 was found in all patients with Brucella-related
native vertebral osteomyelitis [150, 151]. Enzyme-linked
immunosorbent assay (ELISA) has proven to be superior
in complicated cases of brucellosis with negative Coombs
test results and might be of value in patients with
brucellar SD [149]. In a retrospective study including 96
patients with brucellar SD, Colmenero et al. reported that
standard agglutination test titers were ≥ 1:160 for 68% of
patients, and Coombs anti-Brucella or immunocapture-
agglutination test titers were ≥ 1:320 for 79% of patients.
The combined use of standard agglutination test and
Coombs or immunocapture agglutination test enabled cor-
rect serological diagnosis in 89.5% of the 96 patients. In
the same study, the standard agglutination test was >100
in 99% of patients [148].
For patients with suspected SD and risk factors
for Mycobacterium tuberculosis, a PPD test
and an interferon-γ release assay should be
performed
Level of evidence: 4
Tuberculosis (TB) is a very common cause of spinal in-
fection worldwide [19, 21, 23, 152, 153]. In countries
where the incidence of TB is low, tubercular SD is most
often diagnosed in patients originating from endemic
countries and in immune-compromised patients. In
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patients with SD and risk factors for TB infection, a pu-
rified protein derivative (PPD) test or an interferon-γ re-
lease assay may be useful. The interferon-γ release assay
has been associated with higher sensitivity than PPD
[154]. It is important to emphasise that these tests may
yield both false-positive and false-negative findings.
Thus, regardless of test results, in the case of high suspi-
cion of TB infection, an image-guided aspiration biopsy
should be performed in order to perform mycobacterial
tissue cultures.
In recent years, an enzyme-linked immunospot (ELISPOT)
assay has been commercialised (T-SPOT.TB; Oxford
Immunotec, Oxford, UK) that is based on the detection of
interferon-γ released by activated T lymphocytes. The
ELISPOTassay has been demonstrated to provide useful sup-
port in the diagnosis of osteoarticular TB with high sensitivity
and specificity [155–158].
Plain film X-ray should always be performed
in patients with suspicion of spine infection
for purposes of differential diagnostic and follow-up
Level of evidence: 5
Plain radiographs are usually included in the initial imaging
assessment of patients complaining of back pain [41], even
though, considering the low sensitivity and specificity, they
should be avoided when infectious discitis is suspected.
Changes in pyogenic discitis are not apparent on plain radio-
graphs until 2–8 weeks after the initial symptoms [42–44], and
so negative radiographic findings do not exclude infection,
especially in early phases.
No paper has analysed the role of X-rays in the follow-up
of SD as well, and in particular there are no indications that X-
rays might be helpful in the follow-up of patients with
haematogenous SD treated with antibiotics. The actual role
of X-rays, performed with dynamic acquisition, applies to
patients with SD after healing for the evaluation of spine sta-
bility and/or in the follow-up of patients treated for SD with
stabilisation [159].
In haematogenous SD, the first diagnostic imaging
modality is MRI, if patients have no specific
contraindications
Level of evidence: 5
There are no articles specifically addressing this point in the
time range considered for the search. Nevertheless, MRI prop-
erties are well known, and the high sensitivity, specificity, and
accuracy in the diagnosis of SD were underlined in several
studies [54, 159] and in previously published guidelines [36].
MRI may detect infection in the early stages, when other
imaging modalities are still normal (radiography) or nonspe-
cific (nuclear medicine) [159, 160], and so it should be per-
formed as first examination in first diagnosis of SD if the
patient has no specific contraindications.
MRI must be performed with T1, T2, and T2
fat-suppressed or STIR sequences without and
with contrast medium with T1 fat suppression
technique
Level of evidence: 5
There are no recently published trials focused specifically on
MRI acquisition protocols for diagnosis of SD. However, in
clinical practice, MRI studies for suspected SD are usually
performed using the described sequences and contrast medi-
um injection [42, 45, 51, 57, 61, 110].
SPILF guidelines [67] recommend including T1-w, T2-w,
and T2-w sagittal sequences with fat saturation, and complet-
ing the examination with i.v. contrast administration. In addi-
tion, IDSA guidelines [36] suggest the use of i.v. contrast
administration, as Gd-DTPA enhancement may be the first
sign of an acute inflammatory process, and it is useful for
detecting the extension of infectious processes in the
paravertebral spaces.
MRI in suspected spine infection should be performed
with at least a 1.5 Tesla magnet
Level of evidence: 5
There are no reports specifically addressing the question of
whether a 1.5 Tesla magnet is the minimum required for the
diagnosis of SD. However, the vast majority of authors of
published papers performed MRI using 1.5 T or higher mag-
net [55, 110, 161, 162].
CT may be useful for diagnosis only when MRI is
contraindicated, not available, or equivocal
Level of evidence: 3
CT has a minor role in the diagnosis of SD, as it is inferior to
MRI in imaging soft tissue [57]. It represents the best modality
for detecting minimal bony abnormalities, so it may be com-
plementary to MRI [9, 36, 37, 55] and constitutes an alterna-
tive if there are contraindications toMRI. It is also an excellent
modality in early postoperative evaluation and allows guided
biopsy to be performed [64, 163].
CT may be useful when MRI is contraindicated, not avail-
able, or equivocal, as a paper not included in this literature
analysis showed [164].
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In primary and post-surgical SD, if MRI is
contraindicated, the imaging modality of choice is
[18F]FDG-PET/CT
Level of evidence: 2
A comparison between bone scan, 67Ga scintigraphy, and
[18F]FDG-PET/CT showed the best diagnostic accuracy for
[18F]FDG-PET/CT (sensitivity 89%, specificity 88%, PPV
89%, NPV 87%, accuracy 88%) for diagnosing spinal infec-
tion and paraspinal soft tissue infection [82].
The added value of [18F]FDG-PETwas reported specifical-
ly in patients with spinal infections presenting asModic type 1
signal on MRI. [18F]FDG-PET imaging can also provide re-
sults within a short length of time (within 2 h), with resolution
of up to 4–5 mm, and it is useful in the work-up of patients
with metallic implants, since it is not affected by metal-
induced artefacts [88].
The sensitivity and specificity of [18F]FDG-PETwere higher
for the diagnosis of spinal infection when the interpretation
criteria proposed by Hungenbach et al. were applied (sensitivity
86% and specificity 95%). The authors state that the use of
[18F]FDG uptake patterns in the interpretation criteria of
[18F]FDG-PET helps to predict spine infection; in contrast, a
positive [18F]FDG-PET result does not always clearly establish
the cause of increased [18F]FDG uptake [91]. A preliminary
study in 22 patients proposed the use of SUVmax of [
18F]FDG
as a marker of the activity of infectious spondylitis. In this small
patient population, [18F]FDG-PET/CT seemed to complement
MRI for differentiating pyogenic and tuberculous spondylitis
[96]. Published data indicate that [18F]FDG-PET/CT is superior
to 67Ga for diagnosing spine infection and paraspinal soft tissue
infection [82] and should be used in selected cases as an alter-
native to MRI [3, 61, 95–109].
All included papers, both original prospective [82, 88,
90–92, 94, 95, 103, 105, 107–110] and retrospective [111]
studies and reviews [12, 13, 37, 78–80, 115, 165–167], agree
therefore that in patients with suspected SD with contraindi-
cations to MRI, [18F]FDG-PET is a promising and accurate
imaging technique for diagnosis of spine infection with or
without hardware. All papers also agree, however, that the
number of patients studied is still limited.
In post-surgical SD, with or without spinal hardware,
[18F]FDG-PET/CT can detect both spine infection
and soft tissue infection
Level of evidence: 2
Twenty-five [18F]FDG-PET/CT scans performed in children
and young adults with suspected infection of spinal hardware
showed that increased [18F]FDG uptake in the soft tissue and
bone immediately adjacent to the posterior spinal fusion rods
at multiple contiguous vertebral levels was the most common
[18F]FDG-PET/CT finding in the presence of hardware infec-
tion [106]. To avoid the false-positive findings of [18F]FDG-
PET/CT because of nonspecific accumulation of FDG for the
concomitant postoperative inflammation at the surgical site,
the time between spinal hardware placement and [18F]FDG-
PET/CT imaging should be at least 4 months. Moreover, it is
necessary to evaluate both non-attenuation-corrected (NAC)
and attenuation-corrected (AC) PET images in patients with
suspected hardware infection in order to avoid the effect of
metal-induced artefacts on CTAC images. Unfortunately, pa-
tients with hardware loosening have shown focal uptake asso-
ciated with one or two hardware components, usually at a
single vertebral level at the lower or upper extreme of the
hardware construct [106]. This nonspecific sign should al-
ways be considered; inflammatory reactions triggered by spi-
nal implants also may adversely affect specificity [101].
Nevertheless, there is an expanding body of evidence that
supports the use of [18F]FDG-PET and PET/CT for diagnos-
ing spinal infection, especially in patients with MRI contrain-
dications and in the postoperative spine [101].
In another study [18F]FDG-PET/CT and MRI were per-
formed in all patients with spinal hardware for the diagnosis
of spine infection. [18F]FDG-PET/CT was effective in
visualising infection despite the existence of spinal implants,
whereas MRI was not. In addition, the distribution of infection
was visible by PET/CT. Thus, the strongest attribute of PET/CT
is the capacity to specify the true focus of infection, thereby
facilitating selective removal of implants, although it may not
always be necessary in the early phase of surgical site infection
cases. These observations suggest the use of separate surgical
approaches, that is, different pathways for decompression and
screw insertion. In this application, PET/CT seems to provide
an important benefit in choosing which implants should be
preserved or removed [108]. Despite these excellent results, a
large population-based study is warranted.
All papers, both original studies [102, 106, 108] and re-
views [37, 78, 79, 165, 167, 168], included for the evaluation
of this statement agree that [18F]FDG-PET/CT is an accurate
imaging technique for post-surgical spine infection diagnosis
with or without hardware. Even though the number of patients
studied is still limited, evidence-based data indicate that
[18F]FDG-PET/CT has better diagnostic accuracy than other
diagnostic modalities.
In patients with suspected spine infection
and elevated ESR and/or CRP and doubtful MRI, [18F]
FDG-PET/CT should be performed
Level of evidence: 1
MRI is the diagnostic modality of choice for suspicion of
haematogenous spine infection. It presents certain limitations,
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however, particularly when some of the classical imaging
findings are atypical or even absent and in the presence of
spinal hardware or bone fractures. Although most of the pub-
lished series are small, [18F]FDG-PET/CT appears to be supe-
rior to MRI in the detection of spine infection and in the
differentiation of degenerative from infectious end-plate ab-
normalities. [18F]FDG-PET/CT shows high sensitivity and
image resolution; however, specificity remains an issue. In
fact, [18F]FDG may not be able to differentiate infected tissue
from tumours [169]. Furthermore, inflammatory reactions in-
duced by spinal implants may also adversely affect specificity
[101]. Nevertheless, there is an expanding body of evidence
that supports the use of [18F]-FDG PET and PET/CT for di-
agnosing SI, especially when MRI is contraindicated and in
the postoperative spine [101, 115].
All included papers, both original retrospective [106, 111,
139] and prospective [42, 88, 95, 105, 110] studies and re-
views [12, 37, 78–80, 115, 167, 170], agree that [18F]FDG-
PET/CT is a valid tool in the case of inconclusive MRI find-
ings, especially in patients with suspected post-surgical infec-
tions, with or without hardware. From the data in the literature,
evidence clearly emerges that FDG-PET is superior to MRI
for detecting low-grade spondylitis or discitis, and is a useful
adjunct to MRI for differentiating severe spinal degenerative
changes from infection [88].
In patients with suspected spine infection, elevated
ESR and/or CRP, doubtful or unperformable MRI,
and doubtful or unperformable [18F]FDG-PET/CT, a CT
scan should be performed with an image-guided
biopsy
Level of evidence: 2
There are no articles in the available literature specifically
focused on this point.
According to SPILF guidelines [68], when MRI or scintig-
raphy is doubtful, the examination should be repeated if symp-
toms persist, and so a similar approachmay be suggested if the
results of [18F]FDG-PET/CT and/or MRI are doubtful. In ad-
dition, given the highNPVofMRI and PET/CT, a diagnosis of
SD should be excluded if these examinations are negative.
CT scan is indicated in patients who cannot undergo other
imaging studies (MRI or PET/CT); the combination with per-
cutaneous needle aspiration biopsy has high specificity and is
therefore quite useful when positive, especially in patients
with doubtful results at MRI and PET/CT. However, it has
low sensitivity and can miss a substantial proportion of pa-
tients, so surgical debridement and open biopsy are sometimes
required for definitive diagnosis [171]. Even though there are
no evidence-basedmedicine (EBM) data on the benefits of CT
image-guided biopsy, the panel believes that CT-guided biop-
sy should be performed in all cases with high suspicion of
spinal infection and inconclusive or unperformable MRI
and/or PET/CT.
The role of hybrid PET/MRI, although promising,
needs to be evaluated
Level of evidence: 5
No articles describing the potential role of hybrid PET/MRI
for diagnosis of infection were found for the period from 2006
to 2015. We report one study, published in September 2016,
not included in this literature analysis, where the authors note
that the use of FDG-PET/MRI in 30 patients with inconclu-
sive clinical or MRI findings significantly increased diagnos-
tic accuracy for the detection of SD [172].
It is reasonable to think that PET/MRI can be substituted
for [18F]FDG-PET/CT imaging in the diagnosis of spine
infection.
In case of negative MRI or negative [18F]FDG-PET/CT,
the diagnosis of SD should be excluded
Level of evidence: 5
One retrospective [110] and two prospective [103, 110] stud-
ies reported on the high NPVof [18F]FDG-PET/CT and MRI
in patients with suspected haematogenous spine infection. All
published studies from January 2006 to December 2015
underlined the importance of a negative [18F]FDG-PET/CT
for the exclusion of spine infection. Even though there are
no EBM data on the utility of the high NPV of [18F]FDG-
PET/CT in suspected post-surgical spine infection, it is rea-
sonable to think that [18F]FDG-PET/CT, with its high sensi-
tivity, should be the first imaging modality in patients with
secondary SD.
An image-guided aspiration biopsy should be
performed in all patients with suspected SD based
on clinical, laboratory, and imaging studies
Level of evidence: 4
Microbiological diagnosis of SD is extremely important for
choosing the appropriate antimicrobial therapy. The microbi-
ological findings should guide the treatment of SD to improve
the outcome of patients and to limit the use of unnecessary
antibiotics, which can cause adverse effects in humans and
can have negative ecological implications. Empirical broad-
spectrum antibiotic treatment should be administered in cases
of severe sepsis once blood cultures have been taken [36].
Image-guided percutaneous needle aspiration biopsy is a
relatively safe diagnostic tool [58, 59, 171, 173–177]; it can
confirm the suspicion of SD and, importantly, can allow for
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the identification of the aetiological agent causing SD. It has
been reported that cultures of specimens obtained from an
image-guided biopsy may enable a microbiological diagnosis
in 50–60% ormore of cases [116, 174]. Aerobic and anaerobic
cultures should be performed from biopsy specimens, al-
though inoculation of biopsy material into blood culture bot-
tles has been performed by some investigators [65, 116]. To
improve the diagnostic yield, more than one specimen should
be submitted for culture [173].
Mycobacterial, brucellar, and fungal cultures should be ob-
tained in patients with risk factors for these infections [39,
130, 144, 148–151, 178–181].
Molecular diagnostic methods using PCR can be
employed, in addition to standard cultures, to improve the
chance of identifying microorganisms responsible for SD
[141, 182–187]. The use of PCR methods can be particularly
helpful when cultures of biopsy specimens are negative and in
patients who have received prior antimicrobial therapy [141,
188].
PCR is also useful for detecting Mycobacterium
tuberculosis from biopsy specimens. Studies have reported
sensitivity of 95% and specificity of 83% for this test in de-
tecting M. tuberculosis from formalin-fixed, paraffin-
embedded tissue samples in cases of histologically proven
tuberculous spondylitis [182]. Molecular methods may be
used for diagnosis of brucellosis [186, 187].
In patients with risk factors for fungal SD (i.e. immunosup-
pression, long-term indwelling venous catheter, intravenous
drug abuse, neutropenia), biopsy specimens should be sent
for fungal cultures. PCR for the detection of fungal-specific
nucleic acids can increase the sensitivity of standard cultures
[189].
Histological analysis of biopsy specimens should be per-
formed along with microbiological examinations.
Histological analysis can reveal the presence of acute or
chronic inflammation, granuloma, and malignancy. Ziehl–
Neelsen staining for mycobacteria can be helpful.
In some cases, image-guided biopsy might be avoided.
According to the IDSA guideline for the diagnosis and
treatment of native vertebral osteomyelitis, biopsy is not rec-
ommended for patients with a blood culture positive for
S. aureus [35]. In our literature review, we found only one
paper supporting this suggestion, which reported a retrospec-
tive study including 125 patients with vertebral osteomyelitis.
The authors found that 12% of patients (9/74) with microbio-
logically confirmed vertebral osteomyelitis had a previous
finding of bacteraemia with the same pathogen within the
prior year; 24% of patients with S. aureus vertebral osteomy-
elitis had previous S. aureus bacteraemia [146].
According to the IDSA guideline, image-guided biopsy
should not be performed in patients with persistent positive
blood cultures for Staphylococcus lugdunensis, or in dialysis
patients or patients with intravascular devices infected with
other CoNS [36]. No definite recommendations are reported
for patients with suspected SD and concomitant bloodstream
infection with other microorganisms (i.e., Candida species,
Enterobacteriaceae, streptococci, Pseudomonas species); in
these clinical settings, the decision to perform an image-
guided aspiration biopsy remains at the discretion of the
treating physicians [36].
Evaluating the available published data on brucellar SD, it
seems reasonable not to perform image-guided biopsy in pa-
tients coming from or living in areas where brucellosis is
endemic and who have serological tests or blood cultures pos-
itive for Brucella [131, 145, 148]. Colmenero et al. reported
retrospective data on 96 patients who received a diagnosis of
brucellar vertebral osteomyelitis in a tertiary care hospital in
Spain, the large majority of whom were diagnosed through
blood cultures and serological tests for Brucella, with only
34% of patients requiring vertebral biopsy [148].
Antibiotic therapy should be discontinued
or postponed before biopsy
Level of evidence: 4
In clinical practice, the dogma of withholding antibiotics be-
fore obtaining microbiological cultures is well recognised.
Some studies have confirmed the importance of discontinuing
antibiotic therapy in order to improve the chances of obtaining
a microbiological diagnosis of SD. De Lucas et al. found that
diagnostic rates obtained in patients with previous antibiotic
treatment were significantly lower (23% vs 60%, p = 0.027)
than those in patients not exposed to antibiotics [180]. Kim
et al. retrospectively collected data on patients diagnosed with
primary pyogenic vertebral osteomyelitis to identify factors
associated with positive results on microbiological diagnosis.
Duration of antibiotic exposure was assessed and defined as
the time between initiation of antibiotics and obtaining verte-
bral tissue or blood samples for culture. The authors found that
the proportion of patients exposed to antibiotics in the group
with a microbiological diagnosis was significantly lower than
that in the group with negative blood or biopsy cultures
(12.7% vs 46.7%, p = 0.001) [116].
However, some studies found no significant effect of anti-
biotic exposure on the probability of identifying the causative
microorganism in patients with SD [171, 190, 191].
In adult patients with haematogenous SD, the effect of
antibiotic exposure within 14 days pre-biopsy was evaluated.
A multivariate regression model for predicting a positive bi-
opsy culture result among patients with haematogenous SD
showed that a positive biopsy result was found only when
open biopsy was performed. Previous antibiotic treatment
(OR = 2.3; 95% CI: 0.8–6.2; P 5 1), was not significantly
associated with negative culture results [191]. Only 17
(28%) of 60 patients with antibiotic exposure had potentially
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false-negative culture results because of the empirical antibi-
otic treatment. A possible explanation reported by the authors
was that severely ill patients are more likely to be started on
empirical treatment before undergoing biopsy. These patients
may also have more severe infections. Importantly, in this
study, the frequency with which empirical antibiotics matched
the susceptibility of recovered pathogens was assessed, and
the authors found that 63% (38/60) of patients given empirical
antibiotics had been treated with an antibiotic matching sus-
ceptibility and still grew the bacteria [192]. In a further retro-
spective study, Agarwal et al. found no statistical difference in
the rate of biopsy positivity even when the rate of culture
positivity was lower in patients who had been receiving anti-
biotics. Importantly, in this study the duration of antibiotic
exposure was assessed: culture positivity was lower in patients
receiving antibiotics for 4 or more days as compared to pa-
tients exposed to antibiotics for 1–3 days [193]. Similarly,
Kim et al. reported that short-term exposure to antibiotics
had a weak negative effect on culture outcome and that the
effect increased with duration of antibiotic treatment [116].
Even though not all studies were able to demonstrate the
effect of previous antibiotic therapy on the rate of microbio-
logical culture positivity, the panel believes that antibiotics
should be discontinued or postponed before performing a di-
agnostic biopsy. Antimicrobial therapy should not be withheld
in patients with impending sepsis or haemodynamic instabil-
ity. The optimal duration of antibiotic-free time before the
image-guided biopsy has not been established.
In patients with suspected SD based on clinical,
laboratory, and imaging studies and a negative
biopsy (histology and microbiology), another biopsy
should be done
Level of evidence: 4
There are no studies that specifically address the issue of man-
agement of patients with suspicion of SD and non-diagnostic
blood cultures and biopsy specimens results.
In these cases, if not already done, the first step could be to
search for mycobacterial, fungal, or brucellar infection
(through both specific cultures and molecular methods).
Epidemiological evaluation is essential in guiding the choice
of tests to be performed. A second image-guided biopsy
should then be considered.
A retrospective multicenter study evaluated the microbio-
logical diagnostic yield of a second needle biopsy following
an initial negative biopsy in suspected SD. The two percuta-
neous needle biopsies (first and second) had a similar yield
(43% vs 39.4%). A positive first biopsy and a positive second
biopsy following an initial negative one led to microbiological
diagnosis in 79.6% (74/93) versus 44.1% (60/136) of cases,
respectively [179].
Similarly, Friedman et al. reported an increase in the rate of
percutaneous biopsy positivity with repeated biopsy [194].
Percutaneous endoscopic discectomy and drainage
(PEDD) has been also proposed as an option to obtain diag-
nostic specimens. In a retrospective study, Yang et al. com-
pared the diagnostic value of CT-guided biopsy with that of
PEDD. The causative pathogens of SD were found in 90% of
patients in the PEDD group, and the positive culture rate was
superior to that in the CT-guided biopsy group [58]. Another
study reported the usefulness of PEDD for identifying the
causative pathogen of SD [195].
Some experts recommend performing an open biopsy
when image-guided biopsy is inconclusive [37]. The rationale
behind the recommendation is that some studies have reported
a higher rate of culture positivity with surgical samples [174,
196, 197].
Bhavan et al. noted that open biopsy was more likely to
result in pathogen recovery [14 (93%) of 15 open biopsies vs
14 (48%) of 29 needle biopsies; p = 0.003] [119].
In another study, four out of seven negative cultures
(57.1%) from percutaneous CT-guided biopsies were positive
in subsequent cultures of samples obtained during surgery
[120].
In patients with SD diagnosed by [18F]FDG-PET/CT,
a second [18F]FDG-PET/CT scan can be performed
to evaluate the response to antibiotic therapy
Level of evidence: 4
Because [18F]FDG uptake signals increasedmetabolic activity
of the activated cells that are present in infected tissue, semi-
quantitative analysis of the [18F]FDG-PET/CT images can be
useful for evaluating the response to therapy.
Thirty patients with SD underwent dual-time-point acqui-
sition [18F]FDG PET/CT after antibiotic therapy in order to
evaluate treatment response. The maximum and mean SUVs
of the initial and follow-up images were calculated, and the
authors found that the change in maximum SUV was a pow-
erful predictor of residual spinal infection, concluding that
[18F]FDG-PET/CT seemed to be useful for the discrimination
of residual and non-residual spinal infection after treatment
[90].
Riccio et al. proposed another interpretation criterion for
[18F]FDG−PET/CT images during treatment response in pa-
tients with post-surgical pyogenic SD. They state that
[18F]FDG accumulation in bone or soft tissue does indicate
active infection, while [18F]FDG accumulation limited to the
margins of a destroyed disc after antibiotic therapy may be
considered nonspecific and likely represents inflammation
due to mechanically induced reactions. Quantification of ac-
tivity could not reliably differentiate patients with active in-
fection from those without active infection and those with a
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successful response to therapy. The pattern of activity is crit-
ical for accurate interpretation [94]. [18F]FDG-PET/CT, per-
formed for the interim evaluation of response to therapy in
patients with haematogenous spine infection [92], has shown
very high diagnostic accuracy and seems to be a valid tool for
decisions regarding patient treatment. However, two reviews
[166, 168], along with original prospective [90, 92, 94, 105,
107] and retrospective [111, 198] studies, showed inconsistent
results when [18F]FDG-PET/CTwas repeated in patients dur-
ing follow-up, so we can conclude that the number of cases
(150 patients) is still too small to definitively state that
[18F]FDG-PET/CT is the correct diagnostic method for eval-
uation of treatment response.
Conclusions
Clinical evaluation in patients with suspected spinal infection
represents the first step in the diagnostic work-up of the dis-
ease. The presence of symptoms such as new or worsening
spine pain and/or new myelo-radicular disorders, accompa-
nied by fever and/or elevated ESR, CRP, or WBC and/or
bloodstream infection and/or infective endocarditis, should
suggest a diagnosis of SD. Blood cultures (for both aerobic
and anaerobic bacteria) should always be performed in pa-
tients with suspected SD; in patients with epidemiological risk
factors for brucellosis, specific serological tests for Brucella
should also be performed. In the case of suspected TB infec-
tion, a PPD test and an interferon-γ release assay should be
performed. Evaluation of the morphology and/or functionality
of the region of interest is mandatory if the presence of infec-
tion is suspected with clinical evaluation of the patient; the
same evaluation is recommended for the monitoring of treat-
ment and follow-up of the disease. The imaging technique of
choice in suspected spinal infection of haematogenous origin
is MRI in patients without contraindications. MRI must be
performed with T1, T2, and T2 fat-suppressed or STIR se-
quences without and with contrast medium with T1 fat sup-
pression technique. MRI must be performed with at least a 1.5
Tesla magnet.
In patients with inconclusiveMRI results or in the presence
of contraindications to MRI, [18F]FDG-PET/CT is recom-
mended. A negativeMRI can rule out the presence of infective
pathology in the spine, while in the case of inconclusive re-
sults or suspicion of post-surgical spinal infection, PET/CT
with [18F]FDG is suggested. 99mTc-MDP and 67Ga-citrate
scintigraphy can be performed if [18F]FDG-PET/CT imaging
is not available. An image-guided aspiration biopsy should be
performed in all patients with suspected SD based on clinical,
laboratory, and imaging studies. Antibiotic therapy should be
discontinued before biopsy; however, the optimal duration of
antibiotic-free time before image-guided biopsy has not been
established.
A negative [18F]FDG-PET/CT can rule out the presence of
infective pathology of the spine, while with an inconclusive
result a CT image-guided bone biopsy should be performed.
Bone biopsy should eventually be repeated if the first biopsy
finding is negative. Some experts recommend performing an
open biopsy when the image-guided biopsy is inconclusive.
Evidence-based diagnostic flow chart
Based on the above statements and evidence from the pub-
lished literature, we have developed a diagnostic flow chart,
shown in Fig. 1.
In some cases the flow was integrated by consensus
opinion amongst the experts, since not all steps are always
clearly deducible from the literature. The flow chart does
not take into consideration socioeconomic factors or the
availability of diagnostic methods. It also presumes that
all exams are performed at their best (possibly following
procedural guidelines published by each society) and by
expert professionals [199].
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Appendix
Consensus statements
1) SD should be suspected in patients with new or wors-
ening spine pain and/or new myelo-radicular symp-
toms, and at least one of the following: fever, elevated
ESR or CRP, bloodstream infection, or infective
endocarditis.
All papers found: 2289.
Included papers for thorough reading: 183.
Included papers evidence-based statement: 28.
2) CRP, ESR, and WBC counts should always be per-
formed in patients with suspected SD.
P: spine infection OR spinal infection OR vertebral infection
OR vertebral osteomyelitis OR post-surgical spine infection
OR spondylodiscitis OR discitis OR infectious spondylitis.
I: diagnostic methods.
C: none.
O: diagnosis.
All papers found: 2289.
Included papers for thorough reading: 183.
Included papers evidence-based statement: 28.
3) Blood cultures (for both aerobic and anaerobic bacte-
ria) should always be performed in patients with
suspected SD.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis.
I: diagnostic methods.
C: none.
O: diagnosis.
All papers found: 2289.
Included papers for thorough reading: 183.
Included papers evidence-based statement: 30.
4) For patients with suspected SD and epidemiological
risk factors for brucellosis, specific serological tests
should be performed.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis.
I: diagnostic methods.
C: none.
O: diagnosis.
All papers found: 2289.
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Included papers for thorough reading: 183.
Included papers evidence-based statement: 6.
5) For patients with suspected SD and risk factors for
Mycobacterium tuberculosis, a PPD test and an
interferon-γ release assay should be performed.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis.
I: diagnostic methods.
C: none.
O: diagnosis.
All papers found: 2289.
Included papers for thorough reading: 183.
Included papers evidence-based statement: 8.
6) Plain film X-ray should always be performed in pa-
tients with suspicion of spine infection for purposes of
differential diagnostic and follow-up.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious spondyli-
tis = 9683.
I: radiography OR x-ray OR radiographic diagnosis OR
digital radiography OR plain radiography = 497487.
C: none.
O: early diagnosis = 150145.
All papers found: 200.
Included papers for thorough reading: 6.
Included papers evidence-based statement: 6.
7) In haematogenous SD, the first diagnostic imaging
modality is MRI, if patients have no specific
contraindications.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis = 9683.
I: magnetic resonance OR MR OR MRI = 392979.
C: none.
O: diagnosis of spine infection OR diagnosis of vertebral
osteomyelitis OR diagnosis of vertebral infection OR diagno-
sis of soft tissue infection OR diagnosis of paravertebral soft
tissue infection = 5623.
All papers found: 1545.
Included papers for thorough reading: 6.
Included papers evidence-based statement: 5.
8) MRI must be performed with T1, T2, and T2 fat-
suppressed or STIR sequences without and with con-
trast medium with T1 fat suppression technique.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious spondyli-
tis = 9683.
I: MRI must be performed with T1, T2, and T2 fat-
suppressed or STIR sequences without and with contrast me-
dium with T1 fat-suppressed technique = 25.
C: none.
O: diagnosis of spine infection OR diagnosis of vertebral
osteomyelitis OR diagnosis of vertebral infection OR diagno-
sis of soft tissue infection OR diagnosis of paravertebral soft
tissue infection = 5623.
All papers found: 8.
Included papers for thorough reading: 8.
Included papers evidence-based statement: 8.
9) MRI in suspected spine infection should be performed
with at least a 1.5 Tesla magnet.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis = 9683.
I: MRI must be performed with a 1.5 Tesla magnet = none.
C: none.
O: diagnosis of spine infection OR diagnosis of vertebral
osteomyelitis OR diagnosis of vertebral infection OR diagno-
sis of soft tissue infection OR diagnosis of paravertebral soft
tissue infection = 5623.
All papers found: 4.
Included papers for thorough reading: 4.
Included papers evidence-based statement: 4.
10) CT may be useful for diagnosis only when MRI is
contraindicated, not available, or equivocal.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis = 9683.
I: CT OR computed tomography OR CeT = 324788.
C: none.
O: diagnosis of spine infection OR diagnosis of vertebral
osteomyelitis OR diagnosis of vertebral infection OR diagno-
sis of soft tissue infection OR diagnosis of paravertebral soft
tissue infection = 5623.
All papers found: 5.
Included papers for thorough reading: 5.
Included papers evidence-based statement: 5.
11) In primary and post-surgical SD, if MRI is contrain-
dicated, the imaging modality of choice is [18F]FDG-
PET/CT.
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P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis = 9683.
Contraindications to MRI = 120 (none on SD).
I: PETOR PET/CTORFDG-PETOR fluorodeoxyglucose
OR FDG OR positron emission tomography = 62923.
C: none.
O: diagnosis of spine infection OR diagnosis of vertebral
osteomyelitis OR diagnosis of vertebral infection OR diagno-
sis of soft tissue infection OR diagnosis of paravertebral soft
tissue infection = 5377.
All papers found: 94.
Included papers for thorough reading: 30.
Included papers evidence-based statement: 24.
12) In post-surgical SD, with or without spinal hard-
ware, [18F]FDG-PET/CTcan detect both spine infec-
tion and soft tissue infection.
P: post-surgical spine infection OR post-surgical vertebral
infection OR post-surgical vertebral osteomyelitis OR post-
surgical spine OR post-surgical spondylodiscitis OR spinal
hardware = 9683.
I: FDG-PET OR PET OR fluorodeoxyglucose OR FDG
OR positron emission tomography OR PET/CT = 62923.
C: none.
O: diagnosis of spine infection OR diagnosis of vertebral
osteomyelitis OR diagnosis of vertebral infection OR diagno-
sis of soft tissue infection OR diagnosis of paravertebral soft
tissue infection = 5377.
All papers found: 2.
Included papers for thorough reading: 12.
Included papers evidence-based statement: 10.
13) In patients with suspected spine infection and elevat-
ed ESR and/or CRP and doubtful MRI, [18F]FDG-
PET/CT should be performed.
P: inconclusive MR OR doubtful MR OR not diagnostic
MR OR inconclusive MRI OR doubtful MRI OR no diagnos-
tic MRI = 23502.
P: spine infection and elevated ESR and/or CRP = 23299.
I: FDG-PET OR PET OR fluorodeoxyglucose OR FDG
OR positron emission tomography OR PET/CT = 62923.
C: none.
O: diagnosis of spine infection OR diagnosis of vertebral
osteomyelitis OR diagnosis of vertebral infection OR diagno-
sis of soft tissue infection OR diagnosis of paravertebral soft
tissue infection = 5377.
All papers found: 18.
Included papers for thorough reading: 18.
Included papers evidence-based statement: 17.
14) In patients with suspected spine infection, elevated
ESR and/or CRP, doubtful or unperformable MRI,
and doubtful or unperformable [18F]FDG-PET/CT,
a CT scan should be performed with an image-
guided biopsy.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious spondyli-
tis = 9683.
I: Inconclusive FDG-PET OR PET OR inconclusive
fluorodeoxyglucose OR inconclusive FDG OR inconclusive
positron emission tomography OR inconclusive PET/CT OR
doubtful FDG-PET OR doubtful PET/CT =47758.
C: none.
O: CT-guided vertebral biopsy OR vertebral biopsy =
23943.
All papers found: 30.
Included papers for thorough reading: 7.
Included papers evidence-based statement: 7.
15) The role of hybrid PET/MRI, although promising,
needs to be evaluated.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis = 9683.
I: PET/MRI OR PET/MROR hybrid PET/MRI OR hybrid
PET/MR = 949.
C: none.
O: diagnosis of spine infection OR diagnosis of vertebral
osteomyelitis OR diagnosis of vertebral infection OR diagno-
sis of soft tissue infection OR diagnosis of paravertebral soft
tissue infection = 5377.
All papers found: none.
Included papers for thorough reading: none.
Included papers evidence-based statement: none.
16) In case of negative MRI or negative [18F]FDG-PET/
CT, the diagnosis of SD should be excluded.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis = 9683.
I: negative FDG-PET OR negative PET OR negative
fluorodeoxyglucose OR negative FDG OR negative positron
emission tomography OR negative PET/CT = 5800.
negative MR OR negative MRI OR negative magnetic
resonance = 18549.
C: none.
O: absence of spine infection OR absence of vertebral in-
fection OR absence of spondylodiscitis = 131.
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All papers found: 5.
Included papers for thorough reading: 3.
Included papers evidence-based statement: 3.
17) An image-guided aspiration biopsy should be per-
formed in all patients with suspected SD based on
clinical, laboratory, and imaging studies.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis.
I: diagnostic methods.
C: none.
O: diagnosis.
All papers found: 2289.
Included papers for thorough reading: 183.
Included papers evidence-based statement: 28.
18) Antibiotic therapy should be discontinued or post-
poned before biopsy.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis.
I: diagnostic methods.
C: none.
O: diagnosis.
All papers found: 2289.
Included papers for thorough reading: 183.
Included papers evidence-based statement: 9.
19) In patients with suspected SD based on clinical, lab-
oratory, and imaging studies and a negative biopsy
(histology and microbiology), another biopsy should
be done.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis.
I: diagnostic methods.
C: none.
O: diagnosis.
All papers found: 2289.
Included papers for thorough reading: 183.
Included papers evidence-based statement: 11.
20) In patients with SD diagnosed by [18F]FDG-PET/CT,
a second [18F]FDG-PET/CT scan should be per-
formed to evaluate the response to antibiotic therapy.
P: spine infection OR spinal infection OR vertebral infec-
tion OR vertebral osteomyelitis OR post-surgical spine infec-
tion OR spondylodiscitis OR discitis OR infectious
spondylitis = 9683.
I: FDG-PET OR PET OR fluorodeoxyglucose OR FDG
OR positron emission tomography OR PET/CT = 62923.
C: none.
O: response to therapy OR treatment response OR antibi-
otic response = 416536.
All papers found: 19.
Included papers for thorough reading: 9.
Included papers evidence-based statement: 8.
Statements 1, 2, 3, 4, 5, 6, 18, 19, 20 (ESCMID)
(((“spine”[MeSH Terms] OR “spine”[All Fields] OR
“vertebral”[All Fields]) AND (“osteomyelitis”[MeSH
Terms] OR “osteomyelitis”[All Fields])) OR (spinal[All
Fields] AND (“osteomyeli t is”[MeSH Terms] OR
“osteomyelitis”[All Fields])) OR (“discitis”[MeSH Terms]
OR “discitis”[All Fields] OR “spondylodiscitis”[All Fields])
OR (“discitis”[MeSH Terms] OR “discitis”[All Fields] OR
“spondylodiskitis”[All Fields]) OR (“discitis”[MeSH Terms]
OR “discitis”[All Fields] OR “diskitis”[All Fields]) OR
(“discitis”[MeSH Terms] OR “discitis”[All Fields]) OR
(infectious[All Fields] AND (“spondylitis”[MeSH Terms]
OR “spondylitis”[All Fields])) OR (septic[All Fields] AND
(“spondylitis”[MeSH Terms] OR “spondylitis”[All Fields]))
OR (spinal[All Fields] AND (“infection”[MeSH Terms] OR
“infection”[All Fields])) OR (spinal[All Fields] AND
(“infection”[MeSH Terms] OR “infection”[All Fields] OR
“infections”[All Fields])) OR ((“spine”[MeSH Terms] OR
“spine”[All Fields]) AND (“infection”[MeSH Terms] OR
“infection”[All Fields])) OR ((“spine”[MeSH Terms] OR
“spine”[All Fields]) AND (“infection”[MeSH Terms] OR
“infection”[All Fields] OR “infections”[All Fields])) OR
((“spine”[MeSH Terms] OR “spine”[All Fields] OR
“vertebral”[All Fields]) AND (“infection”[MeSH Terms] OR
“infection”[All Fields])) OR ((“spine”[MeSH Terms] OR
“spine”[All Fields] OR “vertebral”[All Fields]) AND
(“infection”[MeSH Terms] OR “infection”[All Fields] OR
“infections”[All Fields])) OR (disk[All Fields] AND
space[All Fields] AND (“infection”[MeSH Terms] OR
“infection”[All Fields])) OR (disk[All Fields] AND
space[All Fields] AND (“infection”[MeSH Terms] OR
“infection”[All Fields] OR “infections”[All Fields])) OR
(d i sc [Al l F ie lds ] AND space [Al l F ie lds ] AND
(“infection”[MeSH Terms] OR “infection”[All Fields])) OR
(d i sc [Al l F ie lds ] AND space [Al l F ie lds ] AND
(“infection”[MeSH Terms] OR “infection”[All Fields] OR
“infections”[All Fields]))) AND ((“diagnosis”[Subheading]
OR “diagnosis”[All Fields] OR “diagnosis”[MeSH Terms])
OR (“diagnosis”[MeSH Terms] OR “diagnosis”[All Fields]
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OR “diagnostic”[All Fields])) AND ((“2006/01/01”[PDAT]:
“2015/12/31”[PDAT]) AND “humans”[MeSH Terms] AND
English[lang] AND “adult”[MeSH Terms]) NOT (“case
reports”[Publication Type] OR “case reports”[All Fields])
All papers found: 2289. Included papers for thorough read-
ing: 183. Included papers evidence-based statement: 61.
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